Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02945514
Other study ID # 16-005208
Secondary ID
Status Completed
Phase N/A
First received October 24, 2016
Last updated February 27, 2018
Start date September 2016
Est. completion date February 28, 2018

Study information

Verified date February 2018
Source Mayo Clinic
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Provide personally tailored dietary suggestions to participants based on the Personalized Prediction Engine (patent pending) owned by DayTwo.


Description:

- Answer personal questions including such things as health information, eating habits and preferences, activity level and intensity.

- Submit a first stool sample via a self-addressed, postage-paid kit that is mailed to you.

- Attend one of the 2 hour connection meetings based on available dates.

- The study team will collect vitals: measurements of height, weight, blood pressure, pulse, waist and hip circumference.

- You will have a Blood collection for study (approximately 35 ml of blood/5 tubes)

- You will be provided a FitBit wrist band that you will wear

- You will be provided a manual blood glucose monitor you will use for pricking finger and measuring blood sugar level at least 4 times per day.

- You will have a continuous blood glucose sensor and monitor inserted by study staff.

- You will use DayTwo's mobile application where you will input food eaten, activity, measurements, medications, and sleep.

- You will be given a second stool kit and instructions for collection.

- You will be asked to eat 4 breakfasts consisting of either bagels and cream cheese or cereal. These foods will be provided for you. Other than these four breakfasts, we would like you to follow your normal eating habits during the collection week.


Recruitment information / eligibility

Status Completed
Enrollment 327
Est. completion date February 28, 2018
Est. primary completion date February 27, 2018
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- 18 years of age or older

- Comprehension of the study objectives and requirements

- Ability to download the DayTwo proprietary mobile application

- Ability to access the DayTwo website for registration and nutrition report

Exclusion Criteria:

- Under 18 years of age

- Pre-diagnosed type I or type II diabetes mellitus

- Pregnancy

- Use of antibiotics or fertility treatments within 3 months prior to participation

- Bariatric weight loss surgery

- Chronic Anemia (hemoglobin of 10g per deciliter or less

- Chronic gastrointestinal disorder (IBD, Celiac, etc.)

- Active cancer or chemotherapy or radiation within 2 years prior to participation

- Condition not allowing to follow the dietary recommendation during the study

- 4 or more alcoholic drinks per day on a regular basis or use of recreational drugs

- Chronic medical condition, treatment, or medication that may affect glucose metabolism (HIV diagnosis, use of steroids or immunosuppressive drugs, etc.)

Study Design


Related Conditions & MeSH terms


Intervention

Other:
DayTwo machine learning algorithm
Personally tailored nutrition insights based on DayTwo machine learning algorithm when combining facets of your postprandial glycemic response to food consumed during collection week and your individual gut microbiome composition

Locations

Country Name City State
United States Mayo Clinic Rochester Minnesota

Sponsors (2)

Lead Sponsor Collaborator
Mayo Clinic DayTwo

Country where clinical trial is conducted

United States, 

References & Publications (1)

Zeevi D, Korem T, Zmora N, Israeli D, Rothschild D, Weinberger A, Ben-Yacov O, Lador D, Avnit-Sagi T, Lotan-Pompan M, Suez J, Mahdi JA, Matot E, Malka G, Kosower N, Rein M, Zilberman-Schapira G, Dohnalová L, Pevsner-Fischer M, Bikovsky R, Halpern Z, Elinav E, Segal E. Personalized Nutrition by Prediction of Glycemic Responses. Cell. 2015 Nov 19;163(5):1079-1094. doi: 10.1016/j.cell.2015.11.001. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Postprandial blood sugar level Baseline through 7 days
See also
  Status Clinical Trial Phase
Completed NCT05029518 - 3-Way Crossover Study to Compare the PK (Pharmokinetics) and to Evaluate the Effect of Food on the Bioavailability Phase 1
Completed NCT05001152 - Taste Assessment of Ozanimod Phase 1
Completed NCT04493255 - A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male Participants Phase 1
Completed NCT03457649 - IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers Phase 1
Completed NCT00995891 - Collection of Blood, Bone Marrow, and Buccal Mucosa Samples From Healthy Volunteers for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Laboratory Research Studies
Completed NCT05043766 - Evaluation of Oral PF614 Relative to OxyContin Phase 1
Completed NCT05050318 - Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively Phase 4
Completed NCT04466748 - A Multiple Ascending Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects Phase 1
Completed NCT00746733 - Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC Phase 1
Recruiting NCT05929651 - Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy Phase 4
Completed NCT05954039 - Evaluation of the Efficacy of a Dietary Supplement on Hair Loss and Hair Aspect N/A
Completed NCT05045716 - A Study of Subcutaneous Lecanemab in Healthy Participants Phase 1
Active, not recruiting NCT02747927 - Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children Phase 3
Completed NCT05533801 - A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants Phase 1
Not yet recruiting NCT03931369 - Adaptation of Thirst to a Single Administration of Tolvaptan (TOLVATHIRST) Phase 2
Completed NCT03279146 - A Single Dose Study Evaluating PK of TXL Oral Formulations in Healthy Subjects Phase 1
Completed NCT06027437 - A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants Phase 1
Recruiting NCT05619874 - Effects of Two Virtual HIFCT Programs in Adults With Abdominal Obesity N/A
Completed NCT05553418 - Investigational On-body Injector Clinical Study N/A
Completed NCT04092712 - Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers Phase 1